Sierra Leone vs Togo: Statin use vs. average non-HDL cholesterol levels
Sierra Leone
2.8
in 2018
Togo
2.8
in 2018
Sierra Leone rank
163rd
Togo rank
163rd
Statin use vs. average non-HDL cholesterol levels over time
- Sierra Leone
- Togo
How they compare
Sierra Leone currently reports 2.8 against 2.8 in Togo, a difference of 0.
The two have swapped places 7 times across 39 shared years of data; in 1980 it was Sierra Leone ahead.
Sierra Leone ranks 163rd and Togo ranks 163rd of 191 countries.
Sierra Leone has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Sierra Leone | Togo | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.55 | 2.47 | 0.08 | Sierra Leone |
| 1990s | 2.6 | 2.57 | 0.03 | Sierra Leone |
| 2000s | 2.69 | 2.67 | 0.02 | Sierra Leone |
| 2010s | 2.8 | 2.79 | 0.0111 | Sierra Leone |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Sierra Leone or Togo?
- Sierra Leone, at 2.8 against 2.8 in Togo as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Sierra Leone and Togo?
- 0, with Sierra Leone ahead.
- How many years of comparable data are there for Sierra Leone and Togo?
- 39 years are reported by both, from 1980 to 2018.
- How do Sierra Leone and Togo rank globally for statin use vs. average non-hdl cholesterol levels?
- Sierra Leone ranks 163rd and Togo ranks 163rd of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.